Outcome of the Board of Directors Meeting held on Friday, May 29, 2026 is attached herewith
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gufic Biosciences reported FY2026 standalone revenue of Rs. 9,404.66 Lakhs, up 14.7% YoY from Rs. 8,198.06 Lakhs. However, standalone net profit declined 9.7% to Rs. 6,314.87 Lakhs from Rs. 6,993.28 Lakhs, primarily due to higher raw material costs and increased finance costs (Rs. 3,661.14 Lakhs vs Rs. 2,311.16 Lakhs). EBITDA margin compressed significantly as total expenses grew faster than revenue. Inventories increased sharply by Rs. 10,759.76 Lakhs year-to-date, tied up in working capital. The Board recommended a final dividend of Re. 0.10 per share (10%). The company also approved investment of Rs. 5.75 Crores in Saraswat Co-operative Bank through subscription to 57.5 lakh equity shares, strengthening its banking relationship. Statutory auditors Mittal Agarwal & Co. issued an unmodified opinion on the audited results.
Revenue growth of ~15% was offset by profit decline of ~10% due to rising input costs and finance expenses. The sharp inventory buildup and increased short-term borrowings (current borrowings up from Rs. 17,987 Lakhs to Rs. 28,013 Lakhs) indicate working capital pressure. While dividend is positive, the earnings decline and margin compression are concerns for shareholders.